The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback